LONDON, Oct 27 (Reuters) - An experimental heart drug fromGlaxoSmithKline called losmapimod failed to work ashoped in the first part of a large clinical trial, the companysaid on Tuesday, dealing a blow to its pipeline of newmedicines.
However, a new shingles vaccine succeeded in a secondpivotal study, demonstrating 90 percent efficacy in preventingthe disease in people over 70 years. GSK plans to submit thevaccine for approval in the second half of 2016.
The British drugmaker gave the updates in separateannouncements, one day before it is due to report third-quarterfinancial results.
(Reporting by Ben Hirschler; Editing by Martinne Geller)